Company news

Ernexa Therapeutics Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate’s (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models

December 2, 2024

Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program

November 24, 2024

Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success

October 29, 2024

Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases

October 16, 2024

Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board

May 7, 2024

Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors

February 19, 2024

Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

January 2, 2024

Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer

December 19, 2023

Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing

December 13, 2023

Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors

October 31, 2023

Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics

September 5, 2023

Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of Directors

September 4, 2023

Eterna Therapeutics Announces Completion of $8.7 Million of Convertible Debt Financing

July 17, 2023

Eterna Therapeutics Appoints Biotech Industry Veterans Brant Binder and Richard Wagner, Ph.D. to Board of Directors

July 10, 2023

Eterna Therapeutics Appoints Megan Yung as Chief Strategy Officer, General Counsel

May 23, 2023

Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics

May 1, 2023

Eterna Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for Up To $10 Million

April 10, 2023

Jeff Karp, Ph.D., Joins Eterna’s Scientific Advisory Board

March 27, 2023

Eterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights

March 19, 2023

Eterna Therapeutics Enters Into Option and License Agreement with Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications

February 21, 2023

Eterna Therapeutics Appoints Matt Angel, Ph.D. as Chief Executive Officer and President

January 3, 2023

Eterna Therapeutics Announces Research Collaboration to Develop Advanced Gene-Edited iPS Cell Therapies

October 31, 2022

← Newer news releases

Decks

The 5 newest of 12 decks. Every deck is listed under its year.